Flatiron Health

What does it take to make #realworlddata work for cancer research and care in the #NHS? Join senior healthcare leaders Prof Ioanna Nixon, Derralynn Hughes, Benjamin Pickwell-Smith, and Arun Sujenthiran MD, alongside Flatiron Health UK Patient Voices Panel Member Linda Galbraith for a discussion on the opportunities and challenges presented by NHS #realworlddata and the role that public-private data partnerships can play, in this upcoming webinar: ⭐ Transforming Cancer Research and Care with Real-World Data 📅 Tuesday, 28th January 2025, 1 - 2PM GMT Register here: https://lnkd.in/eW2V5YHE

Reagan-Udall Foundation for the FDA’s QCARD Initiative recently highlighted the growing need for sponsors to demonstrate early in regulatory engagements that a data source is fit-for-regulatory-purpose. Flatiron’s Head of Regulatory Strategy, Lockwood Taylor, offers insights into the review and Oncology QCARD initial protocol characterization (IPC) published in Pharmacoepidemiology and Safety. He discusses its implications for the use of real-world data (RWD) in regulatory submissions and how Flatiron is already empowering customers with comprehensive support and services to enhance the likelihood of regulatory acceptance for RWD. Learn more about the initiative here: http://spkl.io/6047fb7Tz

A great conversation with Slice of Healthcare! ⏯️ Listen in to Flatiron Health CEO Carolyn Starrett's #SoHCTopEpisode for more on her experience, Flatiron’s vision to transform cancer care and research, and insight into our strategic expansion into the UK, Germany, and Japan to learn from diverse patient experiences globally. https://lnkd.in/gWF4fk7n 

The recent publication from the Reagan-Udall Foundation for the FDA’s QCARD Initiative signals an increasing expectation for sponsors to demonstrate a data source is fit-for-regulatory-purpose very early in a regulatory engagement. Flatiron’s Head of Regulatory Strategy, Lockwood Taylor, broke down the recent review and Oncology QCARD initial protocol characterization (IPC) published in Pharmacoepidemiology and Safety, how he sees it impacting RWD’s use in regulatory submissions, and how Flatiron is already supporting our customers with end-to-end support and services to improve the likelihood of regulatory acceptance of RWD. Read more on the initiative now: http://spkl.io/6047fwS6V

Reimagine the infrastructure of cancer care within a community that values integrity, inspires growth, and is uniquely positioned to create a more modern, connected oncology ecosystem. Apply today: https://shorturl.at/LeL8B

Hear from our Chief Design and Marketing Officer, Jaime Lopez, in a recent Design Better podcast episode for more on how she's leading her team to redesign cancer care everyday ⬇️

There's a growing trend of using real-world data from different countries to support clinical trial data, especially in HTA decisions. However, this raises questions about whether data from one country can apply to another — a concept called transportability. After accounting for differences in population characteristics, this research led by Flatiron Health and NICE - National Institute for Health and Care Excellence found overall survival for patients receiving first line treatment for aNSCLC were similar in the US and UK, suggesting that when local data is unavailable, US data can serve as a reliable alternative, as adjusted US values closely correspond with observed outcomes for UK patients. This research validates transportability as a methodology for using data across borders, with the potential to improve standards of care, speed to access treatments, and provide more confidence in how medicines perform. For more on the findings and why this matters, visit: http://spkl.io/6041fwOfl

このたび、日本の医療専門誌『Precision Medicine 2024年12月号 特集: 腫瘍循環器学の最前線』に、弊社の論文「がん医療に向けたリアルワールドデータ活用」が掲載されました。 本論文では、がん医療の向上を目指したリアルワールドエビデンス生成の重要性を強調するとともに、日本、米国、欧州を跨いだがんデータの活用を可能にする弊社の取り組みを紹介しました。 フラットアイアンヘルス株式会社 戦略的パートナーシップ責任者・日本支社責任者の@Eri Tajima が、本論文を通じて、以下のトピックについて日本市場におけるFlatiron Healthのビジョンと展望を共有しました： 🏥日本市場におけるパートナーシップの拡大と提携機関のネットワーク強化 ✨地域のニーズに応じたデータベースを構築し、レギュラトリーや臨床開発、メディカルアフェアーズなどの領域におけるユースケースに適合したエビデンス生成を加速 💾高度な技術を活用したセキュアな環境で、日本、米国、英国、ドイツを跨いだデータの可視化と統計解析を実現し、がん研究の推進に貢献 論文の詳細をご覧になりたい方は、 印刷版はこちらからご購入いただけます: https://lnkd.in/ejCqbh_H

Recently published in Japan’s Precision Medicine periodical, "Utilization of Real-World Data in Oncology Care,” highlights the importance of generating real-world evidence to improve cancer care and Flatiron’s seamless integration of cancer data across Japan, the US, and Europe. Head of Strategic Partnerships and Head of Office in Japan, Eri Tajima, shared Flatiron Health’s aspirations and vision for the Japan market on fostering impactful collaborations and contributing to the future of evidence-based oncology, including: 🏥 Expanding partnerships in Japan and strengthening our network of collaborating institutions. ✨ Build a robust database that meets local needs and accelerates evidence generation for use cases in the regulatory, clinical development and medical affairs area, ensuring the fit-for-purpose nature of our data. 💾 Leveraging advanced technologies for secure data storage and analysis in order to enable seamless cross-market analysis across Japan, the US, the UK, and Germany to advance real-world oncology research. Available in print here: http://spkl.io/6049fZ5OV

ANNOUNCED TODAY: Flatiron Health to present four abstracts at #SABCS24. Through our research accepted at this year’s conference, Flatiron’s scientists and collaborators continue to showcase our commitment to advancing global oncology evidence generation to unlock critical insights in breast cancer research. Learn more: https://lnkd.in/gc3sAdNT